Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001733397 | SCV001983618 | likely benign | not specified | 2021-09-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002073985 | SCV002444628 | likely benign | Noonan syndrome 9 | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002073985 | SCV002763039 | likely benign | Noonan syndrome 9 | criteria provided, single submitter | clinical testing | ||
Ambry Genetics | RCV004040041 | SCV005025047 | likely benign | Cardiovascular phenotype | 2024-03-07 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003976141 | SCV004791445 | likely benign | SOS2-related disorder | 2019-03-26 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |